|
Active substance |
atezolizumab |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
locally advanced or metastatic urothelial carcinoma in adult, previously untreated patients who are considered cisplatin ineligible |
|
Public documents |
|
|
Last update |
02/03/2018 |
Tecentriq
Last updated on 10/09/2024